Literature DB >> 25431898

The multidisciplinary approach to the treatment of rectal cancer: 2015 update.

Nasarachi E Onyeuku1, Diandra N Ayala-Peacock, Suzanne M Russo, A William Blackstock.   

Abstract

The multidisciplinary approach to the management of rectal cancer continues to evolve with developments in surgery, radiation therapy as well as systemic chemotherapy. Refinement of surgical techniques to improve organ preservation, selective use of neoadjuvant (or adjuvant) therapies, improvements in staging modalities and emerging criteria for the selection of tailored therapies are some of the advancements made over the last three decades. In addition, neoadjuvant treatment alternatives, multimodality sequencing and adaptive therapies based on treatment response continue to be a subject of clinical investigation. The current article reviews the salient topics related to the multidisciplinary treatment of resectable rectal cancer.

Entities:  

Keywords:  adjuvant; cancer; chemotherapy; imaging; radiation; rectal; surgery; targeted therapies

Mesh:

Year:  2014        PMID: 25431898     DOI: 10.1586/17474124.2015.987753

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  3 in total

Review 1.  Recent advances in multidisciplinary approach for rectal cancer.

Authors:  Eiji Oki; Koji Ando; Yuta Kasagi; Yoko Zaitsu; Masahiko Sugiyama; Yuichiro Nakashima; Hideto Sonoda; Kippei Ohgaki; Hiroshi Saeki; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2015-06-23       Impact factor: 3.402

2.  GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.

Authors:  Kunli Zhu; Qianqian Zhao; Jinbo Yue; Pengyue Shi; Hongjiang Yan; Xiaoqing Xu; Renben Wang
Journal:  Oncotarget       Date:  2016-10-18

3.  Laparoscopic versus conventional open surgery in T4 rectal cancer: A case-control study.

Authors:  Xubing Zhang; Qingbin Wu; Tao Hu; Chaoyang Gu; Liang Bi; Ziqiang Wang
Journal:  J Minim Access Surg       Date:  2019 Jan-Mar       Impact factor: 1.407

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.